Healthcare

Novo Nordisk (China) Pharmaceuticals Co., Ltd.

Novo Nordisk A/S is a biopharmaceutical company founded in 1923. Having always been committed to innovation, it is a leader in the field of diabetes. The Company is headquartered in Copenhagen, Denmark, and its products are sold in more than 170 countries and regions. The Tianjin plant of Novo Nordisk (China) Pharmaceutical Co., Ltd. was established in 1995 and settled in TEDA in 2002. It successively completed large-scale expansions in 2004 and 2008. At present, the Company has two production divisions in TEDA, with a total coverage of nearly 130,000 square meters. It has become Novo Nordisk’s only supplier of durable insulin injection device in the world, and an important insulin preparation and filling production base, taking an important strategic position in the Company’s business in the Asia Pacific region.

Novozymes (China) Biotechnology Co., Ltd.

Novozymes is a world leader in biological innovation, committed to enzyme preparation and microbial preparation related business, and providing innovative solutions for the world’s most pressing challenges. Its biological innovation solutions are used in more than 30 industries in more than 130 countries around the world.

Novozymes (China) Biotechnology Co., Ltd. is a multi-purpose enzyme preparation production plant and R&D base invested and built by Novozymes Group in TEDA in 1994. It has been assessed as a headquarters-type organization by Tianjin Municipal Bureau of Commerce. The full scale wash (FSW) laboratory in the plant is the largest FSW test platform of Novozymes in the world. In addition, the first contaminated cloth laboratory of Novozymes in the world is also in this plant. The Company has successively invested RMB 2.8 billion into the plant, and the intelligent production technology and automated control system of the plant are at the leading level both at home and abroad.

Servier (Tianjin) Pharmaceutical Co., Ltd.

Servier (Tianjin) Pharmaceutical Co., Ltd., registered and established in June 2000, is a joint venture between Servier of France and Tianjin Huajin Pharmaceutical Co., Ltd. Since its opening in 2002, the Company has maintained a good sustainable development: in 2008, the new warehouse was expanded and put into use; in 2014, the new QC laboratory building was completed and put into use; in 2016, the factory obtained the production license for the anti-cancer clinical drug trial production workshop; at the beginning of 2018, additional registered capital of EUR 10 million was invested; In 2018, the construction of its new preparation workshop was commenced, which was completed in 2020 and can be used for the production of anti-tumor drugs.

WuXi AppTec (Tianjin) Co., Ltd.

Established in 2006 with a registered capital of RMB 600 million, WuXi AppTec (Tianjin) Co., Ltd. is positioned to be the northern R&D center of WuXi AppTec Group, and is one of the most comprehensive and strongest integrated discovery, research and development service platforms for small molecule chemical drugs. The Company is mainly engaged in preclinical research of small molecule chemical drugs, providing services such as lead compound discovery, drug template synthesis, drug compound library synthesis, and small molecule drug process development. The Company has successively won honors such as China’s Top Ten Leading Enterprises in Service Outsourcing, National High-tech Enterprises, and Tianjin Service Enterprises with Advanced Technologies.

Tianjin Kingyork-Pharmaceuticals Co., Ltd.

Established in November 2010, Tianjin Kingyork-Pharmaceuticals Co., Ltd. is a controlled subsidiary of Tianjin Tianyao Pharmaceutical Co., Ltd. subordinate to Tianjin KingYork Group Co., Ltd. Its registered capital is RMB 600 million and its total asset value is RMB 1.45 billion. Since 2010, KingYork Group has carried out a reconstruction project of KingYork Pharmaceutical Park with KingYork Pharmaceutical as the main implementer, and has invested RMB 800 million to upgrade the Pharmaceutical Park, which has been gradually put into operation since 2013. As a National High-tech Enterprise, Tianjin Science and Technology Leader, Tianjin Science and Technology Little Giant Enterprise, and Tianjin Scientific and Technological Enterprise, KingYork Pharmaceutical is committed to becoming a leading corticosteroid drug R&D and production base in the world.

CP Premix (Tianjin) Co., Ltd.

Since it was put into operation in August 1993, CP Premix (Tianjin) Co., Ltd. has successively established 8 customer service centers in Henan, Xinjiang, Ningxia, Shandong and other places. The Company has an annual production capacity of 160,000 tons and an annual turnover of more than RMB 900 million.

The Company has a quality control and R&D center of 600 square meters, world-leading precision inspection equipment, a large number of high-quality talents and a strict quality control center. The Company has obtained 3 national invention patents and 15 utility model patents for its products.

Sino Medical Sciences Technology Inc.

Sino Medical Sciences Technology Inc. was established in September 2007 and listed in Shanghai in October 2019. The Company has established a R&D, production and operation system with considerable scale and international level. Its business covers key areas of interventional therapy such as cardiovascular diseases, cerebrovascular diseases, and structural heart diseases.

By virtue of the research in these years, the Company has developed 8 key technologies and 13 product lines in different fields; it has more than 200 invention patents and exclusive licenses across the world; 11 papers on the clinical research results of its products have been published on domestic and international core journals; it has undertaken 7 national and provincial scientific research projects.

Asymchem Life Science (Tianjin) Co., Ltd.

Established in 2005, Asymchem Life Science (Tianjin) Co., Ltd. is a one-stop service platform integrating drug synthesis technology research, biological and genetic engineering technology development, professional analysis and testing, process safety testing and drug production. It is a national high-tech enterprise.

Always taking technology as the driving force, the Company has developed a disruptive green pharmaceutical technology with independent intellectual property rights, and has raised it to international standards through further industrialization of the technology. In August 2017, the Company was successfully selected into the demonstration list of “Green Factory of the Ministry of Industry and Information Technology”, becoming the only one of the first-batch enterprises so selected in Tianjin.

BSI (Tianjin) Foods Co., Ltd.

Established in 1997, BSI (Tianjin) Foods Co., Ltd. is China’s first professional cheese manufacturer solely owned by a foreign investor (SAVENCIA Group of France).

At present, the Company’s Milkana reprocessed cheese has become the No. 1 brand in the domestic mid-to-high-end cheese retail market. At the same time, its growth remains robust in the fields of professional catering and BTOB, with mozzarella shredded cheese and cheese slices as its main products. Having passed several international quality certifications such as HACCP and many international and domestic fast food chain certifications, the Company is a leader in the development of the Chinese cheese market.

Tianjin Tianyao Pharmaceuticals Co., Ltd.

Tianjin Tianyao Pharmaceutical Co., Ltd. was established in 1999 and listed on the Shanghai Stock Exchange in 2001 with the stock code 600488. At present, the Company controls or holds the shares of 16 companies, with total assets of RMB 5.281 billion.

The Company is mainly engaged in the research, development, production and sale of corticosteroids and amino acid APIs and preparations. It is one of the early batches of pharmaceutical companies in China that obtained GMP certificates for corticosteroids APIs, and one of the first batch of APIs and preparations manufacturers in Tianjin that have passed all national GMP certifications. Jinyao Pharmaceutical, a controlled subsidiary of the Company and a leading technological company in Tianjin, is committed to becoming a domestic R&D and production base of corticosteroid preparations, and is currently a national high-tech enterprise and a technological enterprise of Tianjin.

Tianjin Tanabe Seiyaku Co., Ltd.

Tianjin Tanabe Seiyaku Co., Ltd. was jointly funded and established by Tianjin Lisheng Pharmaceutical Co., Ltd. (formerly Tianjin Lisheng Pharmaceutical Factory) and Japan Tanabe Seiyaku Mitsubishi Pharmaceutical Co., Ltd. (formerly Tanabe Seiyaku Co., Ltd.), and officially started its operation in November 1994. The Company has a registered capital of USD 16.23 million, a coverage of 53,200 square meters, and an annual production capacity of 900 million tablets. At present, the Company has ten drug products, among which the cerebrovascular drugs include Hexinshuang Tablets, Hebeishuang Capsules, Hebeishuang Injections, Dashuang, ANPLAG, NOVASTAN, and so on, and the digestive system drugs include Shuli Qineng, Gaishuang, and so on. In 2019, the Company’s sales revenue reached RMB 364 million.

Tianjin Yakult Co., Ltd.

Tianjin Yakult Co., Ltd. was established in 2007 and officially put into production in 2011. The Company mainly produces and sells protein drinks (active lactic acid bacteria milk drinks) and other products. In 2014, the second Yakult plant formally started production. In 2016, Yakult began to produce low-sugar products. At present, Yakult has totally 8 production lines with a total production capacity of 3.55 million bottles per day.

In the early days after the establishment of the factory, Yakult specially designed a visitor channel, where consumers can watch Yakult’s modern production processes, experience Yakult’s corporate culture, and taste fresh Yakult products.

Tianjin Tingyi Food Co., Ltd.

Tianjin Tingyi Food Co., Ltd., established in 1992, is the first instant noodle manufacturing enterprise invested and established by Ting Hsin International Group in the Chinese Mainland. The Company mainly produces “Master Kong” series instant noodles. Since its establishment, the Company has maintained a stable and high-speed development. In 2019, the Company had a total sales revenue of RMB 5.7 billion, and total profit and taxes of RMB 930 million.

Tianjin Tingyuan Food Co., Ltd.

Tianjin Tingyuan Food Co., Ltd. was established in 1995, with a coverage of 45,900 square meters, a registered capital of USD 37 million and total investment of USD 85 million. As a subsidiary of Master Kong Holdings, the Company is mainly engaged in production and sale of pastries, biscuits, snacks and other food, and has launched characteristics products such as “Xiangmibing”, “Xuemibing”, “soda sandwich biscuits” and “Meiweisu”. Up to now, Tingyuan Food has grownto a large-scale and influential food company.

Tianjin WeiLianDe Medical Instrument Sales Co., Ltd.

Tianjin Weiliande Orthopedic Technology Co., Ltd. is a subsidiary of Naton Group, a professional orthopedic technology and product promotion enterprise, and the exclusive agent of WALDEMER LINK of German for its orthopedic products in China. The Company has established a complete and professional product sale and technology promotion system, providing customers with a full range of artificial joint and internal fixation product and related technical services. The LINK products and other products sold by the Company are among the best in the imported orthopedics market of China.

Tianjin Nestlé Co., Ltd.

Founded in 1866, Nestlé is a world-renowned food and beverage company with more than 2,000 brands worldwide, involving many fields such as infant nutrition, drinking water, coffee, pet food, professional solutions, dairy products, health sciences, frozen food and condiments. Tianjin Nestlé Co., Ltd. was established in 1994 with a coverage of 1.2 million square meters. It is a wholly-owned enterprise of the Nestlé Group of Switzerland, and mainly produces chocolate wafers, candies and ice cream products. As a leading food manufacturer, Tianjin Nestlé is constantly committed to product development and technological innovation, and has always focused on food, personnel and environmental safety.